RTP Mobile Logo
This activity is intended for medical oncologists, oncology fellows, oncology nurses and other healthcare providers involved in the treatment of breast cancer.

Breast cancer remains the most frequently diagnosed cancer in women, and in 2017 in the United States alone it is estimated that the disease will culminate in an estimated 255,180 new cases and 41,070 deaths. The current clinical management of breast cancer is multidisciplinary and includes surgical resection of local disease with or without radiation therapy and the treatment of systemic disease with cytotoxic chemotherapy, endocrine therapy, biologic therapy or combinations of these approaches. The indications for and utility of these local and systemic treatment options are largely based on a number of prognostic and predictive risk factors present in the patient or her tumor at the time of diagnosis. Although the diagnosis and treatment of breast cancer are still in many ways more advanced than in other solid tumors, challenging issues in the basic management of this disease continue to require refinement. Many areas of controversy persist within the academic and community settings despite several consensus- and evidence-based treatment guidelines that aim to assist clinicians in making breast cancer management decisions in a dynamic clinical and research environment. To provide clinicians with therapeutic strategies to address the disparate needs of patients with breast cancer, this program will present the perspectives of clinical investigators on key challenges and controversies to address the existing management uncertainties of clinician learners and help keep them up to date in a continuously evolving therapeutic landscape.


  • Compare and contrast faculty recommendations regarding treatment for premenopausal and postmenopausal women with ER-positive/HER2-negative breast cancer who experience metastatic disease progression during or after completion of adjuvant endocrine therapy.
  • Assess the role of CDK4/6 inhibitors in the treatment algorithm for patients with de novo or recurrent metastatic ER-positive/HER2-negative breast cancer.
  • Review faculty preferences for the treatment of metastatic ER-positive/HER2-negative breast cancer after disease progression on CDK4/6 inhibitor-based therapy.

Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CME credit is no longer available for this issue

CME credit is no longer available for this issue

This CME activity consists of a text component.
CME credit is no longer available for this issue

Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Sarat Chandarlapaty, MD, PhD
Medical Oncologist
Memorial Sloan Kettering Cancer Center
New York, New York

Consulting Agreements: Agendia Inc, AstraZeneca Pharmaceuticals LP, Chugai Pharmaceutical Co Ltd, MacroGenics Inc, Sermonix Pharmaceuticals; Contracted Research: Lilly, Novartis.

William J Gradishar, MD
Betsy Bramsen Professor of Breast Oncology and Professor of Medicine
Deputy Director, Clinical Network
Robert H Lurie Comprehensive Cancer Center of Northwestern University
Director, Maggie Daley Center for Women’s Cancer Care
Deputy Chief, Division of Hematology/Oncology
Northwestern University Feinberg School of Medicine
Chicago, Illinois

No relevant conflicts of interest to disclose.

Kathy D Miller, MD
Co-Director, IU Simon Cancer Center Breast Cancer Program
Ballvé-Lantero Scholar in Oncology
Professor of Medicine, Division of Hematology/Oncology
The Indiana University Melvin and Bren Simon Cancer Center
Indianapolis, Indiana

Contracted Research: Astellas Pharma Global Development Inc, Genentech BioOncology, Medivation Inc, a Pfizer Company, Merrimack Pharmaceuticals Inc, Novartis, Pfizer Inc, Taiho Oncology Inc; Data Monitoring Committee: ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Merck.

Ruth M O’Regan, MD
Professor of Medicine
Chief, Division of Hematology/Oncology
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin

Advisory Committee: bioTheranostics Inc, Lilly, Pfizer Inc; Contracted Research: Novartis, Pfizer Inc.

Lee S Schwartzberg, MD
Medical Director, The West Clinic
Clinical Professor of Medicine
University of Tennessee School of Medicine
Memphis, Tennessee

Consulting Agreements: Amgen Inc, Bristol-Myers Squibb Company, Genomic Health Inc, Pfizer Inc, Spectrum Pharmaceuticals Inc; Speakers Bureau: Genentech BioOncology.

Melinda L Telli, MD
Assistant Professor of Medicine
Stanford University School of Medicine
Stanford, California

Advisory Committee: Tesaro Inc, Vertex Pharmaceuticals Incorporated; Consulting Agreement: AstraZeneca Pharmaceuticals LP; Contracted Research: Abbott Laboratories, Calithera Biosciences, Genentech BioOncology, Medivation Inc, a Pfizer Company, OncoSec Medical, PharmaMar, Vertex Pharmaceuticals Incorporated.

Sara M Tolaney, MD, MPH
Department of Medical Oncology
Dana-Farber Cancer Institute
Assistant Professor in Medicine
Harvard Medical School
Boston, Massachusetts

Contracted Research: Genentech BioOncology, Lilly, Merck, Novartis, Pfizer Inc.

Denise A Yardley, MD
Senior Investigator, Breast Cancer Research
Sarah Cannon Research Institute 
Tennessee Oncology PLLC
Nashville, Tennessee

Advisory Committee: Novartis; Speakers Bureau: Eisai Inc, Genentech BioOncology.

EDITOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma, Adaptive Biotechnologies, Agendia Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma Corp, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Medivation Inc, a Pfizer Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro Inc, Teva Oncology and Tokai Pharmaceuticals Inc.

RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no relevant conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from Celgene Corporation, Genentech BioOncology, Genomic Health Inc, Lilly and Novartis.

Hardware/Software Requirements:
A high-speed Internet connection
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
Adobe Flash Player 10.2 plug-in or later
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio

Last review date: June 2017
Expiration date: June 2018